Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?

Clinical Endocrinology

Volumn 61, Issue 6, 2004, Pages 704-710

  Salvatori, Massimo ^a,c   Perotti, Germano ^a   Rufini, Vittoria ^a   Maussier, Maria Lodovica ^a   Dottorini, Massimo ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b BUFALINI HOSPITAL   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; THYROGLOBULIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CATHETER ABLATION; CHILD; FEMALE; HUMAN; IODINE 131 UPTAKE TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; CARCINOMA; EVALUATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK; SCINTISCANNING; THYROID GLAND; THYROID TUMOR; UNNECESSARY PROCEDURE; WHOLE BODY COUNTING;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE; UNNECESSARY PROCEDURES; WHOLE-BODY COUNTING;

EID: 10844287139     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2004.02153.x     Document Type: Article

References (25)

1. Bachelot, A., Cailleaux, A.F., Klain, M., Baudin, E., Ricard, M., Bellon, N., Caillou, B., Travagli, J.P. & Schlumberger, M. (2002) Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid, 12, 707-711.
2. 131I on postsurgical thyroid remnants. Journal of Nuclear Medicine, 1, 2038-2042.
3. 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nuclear Medicine Communications, 17, 687-691.
4. 131I scintigraphy. Nuclear Medicine Communications, 21, 529-532.
5. Fatourechi, V., Hay, I.D., Mullan, B.P., Wiseman, G.A., Eghbali-Fatourechi, G.Z., Thorson, L.M. & German, C.A. (2000) Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid, 10, 573-577.
6. Huic, D., Medvedec, M., Dodig, D., Popovic, S., Ivancevic, D., Pavlinovic, Z. & Zuvic, M. (1996) Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I. Nuclear Medicine Communications, 17, 839-842.
7. 131I. European Journal of Nuclear Medicine and Molecular Imaging, 29, 1421-1427.
8. Leger, F.A., Izembart, M., Dagousset, F., Barritoult, L., Baillet, G., Chevalier, A. & Clerk, J. (1998) Decreased uptake of therapeutic doses ofiodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. European Journal of Nuclear Medicine, 25, 242-246.
9. 131I whole body scintigraphy in thyroid cancer patients. Quarterly Journal of Nuclear Medicine, 43, 188-194.
10. Mazzaferri, E.L., Robbins, R.J., Spencer, C.A., Braverman, L.E., Pacini, F., Wartofsky, L., Haugen, B.R., Sherman, S.I., Cooper, D.S., Braunstein, G.D., Lee, S., Davies, T.F., Arafah, B.M., Ladenson, P.W. & Pinchera, A. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 1433-1441.
11. Morris, L.F., Waxman, A.D. & Braunstein, G.D. (2003) Thyroid stunning. Thyroid, 13, 333-340.
12. 131I uptake of remaining tissue in patients with differentiated thyroid carcinoma after thyroidectomy. Nuclear Medicine Communications, 9, 262-266.
13. Muller-Gartner, H.W. & Schneider, C. (1988) Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer, 61, 976-981.
14. 131I scans: their role in the management of thyroid cancer. Thyroid, 7, 281-284.
15. Sabin, L.H. & Wittekind, C.H. (1997) UICC: TNM Classification of Malignant Tumors, 5th edn. Wiley-Liss, New York.
16. Sarkar, S.D., Kalapparambath, T.P. & Palestro, C.J. (2002) Comparison of 123-I and 131-I for whole-body imaging in thyroid cancer. Journal of Nuclear Medicine, 43, 632-634.
17. Schlumberger, M. & Baudin, E. (1998) Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. European Journal of Endocrinology, 136, 249-252.
18. Shapiro, B., Rufini, V., Jarwan, A., Geatty, O., Kearfott, K.J., Fig, L.M., Kirkwood, I.D. & Gross, M.D. (2000) Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole 131-I scans in patients with thyroid cancer. Seminars on Nuclear Medicine, 30, 115-132.
19. Sherman, S.I., Tielens, E.T., Sostre, S., Wharam, M.D. & Ladenson, P.W. (1994) Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 78, 629-634.
20. 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clinical Endocrinology, 55, 515-521.
21. 131I. Journal of Nuclear Medicine, 42, 975-983.
22. Spencer, C.A., Lo Presti, J.S., Fatemi, S. & Nicoloff, J.T. (1999) Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid, 9, 435-441.
23. 131I therapy. Clinical Nuclear Medicine, 14, 793-800.
24. Wartofsky, L., Sherman, S.I., Gopal, J., Schlumberger, M. & Hay, I.D. (1998) The use of radioactive iodine in patients with papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 83, 4195-4203.
25. Westbury, C., Vini, L., Fischer, C. & Harmer, C. (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid, 10, 171-176.